Skip to main content
. 2021 Nov 16;22(22):12368. doi: 10.3390/ijms222212368

Table 2.

Potential ocular drugs under clinical trial and approved by FDA.

Trademark/Drug Name Drug Molecule Clinicaltrials.gov Identifier Status
INVELTYS Loteprednol etabonate NCT02163824NCT02793817 FDA 1 approved
Bromsite Bromfenac NCT01576952 FDA 1 approved
Dexasite Dexamethasone NCT03192137NCT01543490 Phase III
OCS-01 Dexamethasone NCT04130802 Phase II
RX-10045 Resolvin E1 NCT02329743 Phase II

1 FDA—Federal Drug Agency, USA.